Neuphoria Therapeutics Inc (NEUP) - Total Assets
Based on the latest financial reports, Neuphoria Therapeutics Inc (NEUP) holds total assets worth $36.60 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check NEUP total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Neuphoria Therapeutics Inc - Total Assets Trend (1999–2025)
This chart illustrates how Neuphoria Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Explore NEUP long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Neuphoria Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
Neuphoria Therapeutics Inc's total assets of $36.60 Million consist of 52.6% current assets and 47.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 49.7% |
| Accounts Receivable | $11.95 Million | 27.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.30 Million | 16.8% |
| Goodwill | $13.13 Million | 30.2% |
Asset Composition Trend (1999–2025)
This chart illustrates how Neuphoria Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NEUP company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuphoria Therapeutics Inc's current assets represent 52.6% of total assets in 2025, a decrease from 100.0% in 1999.
- Cash Position: Cash and equivalents constituted 49.7% of total assets in 2025, up from 40.4% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is goodwill at 30.2% of total assets.
Neuphoria Therapeutics Inc Competitors by Total Assets
Key competitors of Neuphoria Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Neuphoria Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.04 | 2.06 | 0.74 |
| Quick Ratio | 9.04 | 2.06 | 0.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $20.80 Million | $2.27 Million | $-1.85 Million |
Neuphoria Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Neuphoria Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.78 |
| Latest Market Cap to Assets Ratio | 0.53 |
| Asset Growth Rate (YoY) | 57.1% |
| Total Assets | $43.44 Million |
| Market Capitalization | $23.23 Million USD |
Valuation Analysis
Below Book Valuation: The market values Neuphoria Therapeutics Inc's assets below their book value (0.53x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Neuphoria Therapeutics Inc's assets grew by 57.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neuphoria Therapeutics Inc (1999–2025)
The table below shows the annual total assets of Neuphoria Therapeutics Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $43.44 Million | +57.11% |
| 2024-06-30 | $27.65 Million | +42.57% |
| 2023-06-30 | $19.39 Million | -56.83% |
| 2022-06-30 | $44.93 Million | +10.20% |
| 2021-06-30 | $40.77 Million | +72.17% |
| 2020-06-30 | $23.68 Million | -36.99% |
| 2019-06-30 | $37.58 Million | -21.38% |
| 2018-06-30 | $47.80 Million | -26.02% |
| 2017-06-30 | $64.61 Million | -1.70% |
| 2016-06-30 | $65.72 Million | +23.95% |
| 2015-06-30 | $53.02 Million | -13.44% |
| 2014-06-30 | $61.25 Million | +25.20% |
| 2013-06-30 | $48.93 Million | +53.71% |
| 2012-06-30 | $31.83 Million | -13.19% |
| 2011-06-30 | $36.67 Million | +36.91% |
| 2010-06-30 | $26.78 Million | +34.22% |
| 2009-06-30 | $19.95 Million | -26.34% |
| 2008-06-30 | $27.09 Million | +3.62% |
| 2007-06-30 | $26.14 Million | +78.69% |
| 2006-06-30 | $14.63 Million | +12.53% |
| 2005-06-30 | $13.00 Million | +24.28% |
| 2004-06-30 | $10.46 Million | +23.50% |
| 2003-06-30 | $8.47 Million | -5.01% |
| 2002-06-30 | $8.92 Million | +61.36% |
| 2001-06-30 | $5.53 Million | +74.38% |
| 2000-06-30 | $3.17 Million | +2128.83% |
| 1999-06-30 | $142.19K | -- |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disord… Read more